Adventrx Antiviral Shows Promise Against Bird Flu
Posted on: Tuesday, 21 March 2006, 21:00 CST
Additional preclinical studies have demonstrated that Adventrx Pharmaceuticals' antiviral drug, Thiovir, is active against a chimeric avian/human influenza virus anfd influenza A.
Adventrx plans to further investigate Thiovir efficacy against multiple H5N1 strains of avian influenza in both in vitro and in vivo studies in collaboration.
"We are encouraged by the results from two independent labs confirming Thiovir activity against multiple influenza viruses," said Evan Levine, president and CEO for Adventrx. "We will continue to investigate Thiovir as a therapy for influenza viruses, including bird flu, and we look forward to announcing additional results."
Thiovir is intended to deliver the benefits of the antiviral drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved bioavailability. Adventrx currently plans to file an investigational new drug application with the FDA in the first half of 2006 for testing of Thiovir in patients with HIV/AIDS.
Source: Datamonitor
Related Articles
- In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
- Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians' Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
- Identify the Commercial Opportunities to Develop Antibacterials That Are Effective Against Drug-Resistant Pathogens
- ADVENTRX Presents Broad Antiviral Activity for Thiovir
- Vietnam Enhances International Cooperation Against Drug Trafficking
- Russian Official Gives Details of Drive Against Drug-Trafficking
- China Seizes 2,182.3 Kg of "Ice" in Campaign Against Drugs (More Added)
- Nutra Pharma Announces RPI-MN Shows Positive Effects Against Drug-Resistant Strains of HIV
- Avian Influenza Viruses Increase Drug Resistance in Asia: Study
- Lawsuits to Come From Britain Against Drug-Maker Merck
 |
 |
User Comments (0)
RSS Feeds